As a member company of EFPIA, AbbVie is committed to ensuring that the nature and scope of transfers of value (ToV) with Patient Organizations (P.O.) are clear and transparent to the public. Therefore, AbbVie has published applicable ToV provided directly or indirectly to P.O. for the 2023 calendar year.

ToV to P.O. are disclosed on an individual basis. The internet disclosure will remain available for a period of no more than three (3) years from the date of publication.

This Methodological Note provides guidance on how AbbVie has recorded and publicly reported this information in accordance with the “EFPIA Code of Practice” on Relationships between the Pharmaceutical Industry and Patient Organisations.

**Reporting period / Reportable ToV:**
The AbbVie 2023 disclosure includes applicable ToV during the period between 1 January 2023 and 31 December 2023.

**Transparency Acknowledgment from P.O. (where applicable):**
Agreements between AbbVie and P.O. relating to ToV may have included a Transparency section where P.O. were notified of AbbVie’s Transparency disclosure obligations.

**Cross Border Interactions:**
Reportable ToV provided by AbbVie (worldwide) to European P.O. have been included.

**ToV Definitions:**

**P.O. ToV Definition, such as:**
- Fee for Service and Consultancy
  - Speaker fee (including associated preparation work)
  - Advisory Boards and other consultancy engagements (including associated preparation work)
  - Chairing a meeting
  - Educational/Scientific Events

- Related expenses agreed upon in the Fee for Service or consultancy contract, such as:
  - Flights
  - Hotel
  - Other transportations costs (train, taxi, bus, underground)

- Contribution to the cost of events e.g., sponsorship for registration fees, travel, and accommodation, such as:
  - Congress/Meeting registration
  - Flights
  - Hotel
  - Other transportations costs (train, taxi, bus, underground)

- Sponsorship agreements with P.O./third parties (professional conference organizers) appointed by P.O. to manage an event, such as partially funded independent education
events. When sponsorship also includes catering costs and any other forms of funding (e.g., logistical costs) as part of a sponsorship package these are disclosed as a ToV (sponsorship).

- Where AbbVie sponsorship is provided through a professional conference organizer (PCO), the ToV will be disclosed in the name of the recipient P.O.
- Where a vendor is organizing an event (via AbbVie-provided sponsorship) on behalf of more than one P.O., then the ToV will be disclosed in the name of each P.O. recipient.

- Donations and Grants to P.O. and Benefits in Kind to P.O.

**Date Methodology:**
AbbVie followed the date methodology when determining which ToV are in scope for current reporting cycle:

**Event Date** is defined as the date the expense occurred. ToV related to the following categories will use the Event Date when determining applicability for current year reporting requirements (e.g., did the event occur within the reporting period 1 January 2023 to 31 December 2023).

- Fee for Service and Consultancy: Expenses
- Contribution to Cost of Events: Registration Fees
- Contribution to Cost of Events: Travel and Accommodation

**Paid Date** is defined as the date the payment was provided to the covered recipient. ToV related to the following categories use the Paid Date when determining applicability for current year reporting requirements (e.g., did the payment occur within the reporting period 1 January 2023 to 31 December 2023).

- Fee for Service and Consultancy: Fee
- Contribution to Cost of Events: Sponsorship Agreements
- Grants and Donations

**VAT:**
Where applicable, disclosure of payments may include VAT except for grants and donations. Cross border ToV may or may not include VAT depending on the submitting source.

**Currency:**
All information is reported in local currency of the country of the P.O (except Serbia, which uses US Dollar). Cross border ToV may be reported in US Dollar or Euro.

**Exchange Rate:**
Where ToV were captured in foreign currency, amounts were converted to local currency based on Monthly Average Rates.

**Multiyear Contracts:**
For multi-year contracts, disclosure includes as far as possible only ToV which occurred during the reporting period (1 January 2023 to 31 December 2023).

**Post Publication Disputes**
AbbVie will review and investigate disputes with P.O. relative to our transparency reports. Any changes resulting from this review will be published in an updated report.